Various vaccine platforms in the field of COVID-19

[1] Sultana J(2020)Challenges for drug repurposing in the COVID-19 pandemic era Front Pharmacol 11 1657-25

[2] Crisafulli S(2021)COVID-19 vaccines: the status and perspectives in delivery points of view Adv Drug Deliv Rev 170 1-269

[3] Gabbay F(2020)Natural history of COVID-19 and current knowledge on treatment therapeutic options Biomed Pharmacother 129 110493-216

[4] Lynn E(2018)New vaccine technologies to combat outbreak situations Front Immunol 9 1963-1973

[5] Shakir S(2021)Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England Nature 593 266-1820

[6] Trifirò G(2013)Novel vaccine strategies against emerging viruses Curr Opin Virol 3 210-620

[7] Chung JY(2021)SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection MedRxiv 593 142-3018

[8] Thone MN(2020)Developing COVID-19 vaccines at pandemic speed N Engl J Med 382 1969-216

[9] Kwon YJ(2010)Coronavirus genomics and bioinformatics analysis Viruses 2 1804-85

[10] Dos Santos WG(2020)Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review Diagn Microbiol Infect Dis 98 115094-22

[1] Sultana J(2020)Challenges for drug repurposing in the COVID-19 pandemic era Front Pharmacol 11 1657-25

[2] Crisafulli S(2021)COVID-19 vaccines: the status and perspectives in delivery points of view Adv Drug Deliv Rev 170 1-269

[3] Gabbay F(2020)Natural history of COVID-19 and current knowledge on treatment therapeutic options Biomed Pharmacother 129 110493-216

[4] Lynn E(2018)New vaccine technologies to combat outbreak situations Front Immunol 9 1963-1973

[5] Shakir S(2021)Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England Nature 593 266-1820

[6] Trifirò G(2013)Novel vaccine strategies against emerging viruses Curr Opin Virol 3 210-620

[7] Chung JY(2021)SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection MedRxiv 593 142-3018

[8] Thone MN(2020)Developing COVID-19 vaccines at pandemic speed N Engl J Med 382 1969-216

[9] Kwon YJ(2010)Coronavirus genomics and bioinformatics analysis Viruses 2 1804-85

[10] Dos Santos WG(2020)Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review Diagn Microbiol Infect Dis 98 115094-22